193 related articles for article (PubMed ID: 34438241)
1. Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy.
Hassel JC; Livingstone E; Allam JP; Behre HM; Bojunga J; Klein HH; Landsberg J; Nawroth F; Schüring A; Susok L; Thoms KM; Kiesel L; Berking C
ESMO Open; 2021 Oct; 6(5):100248. PubMed ID: 34438241
[TBL] [Abstract][Full Text] [Related]
2. [Fertility, teratogenicity, and contraception during therapy with BRAF/MEK inhibitors].
Livingstone E; Berking C
Dermatologie (Heidelb); 2023 Jul; 74(7):496-500. PubMed ID: 37289207
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
5. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
7. [Systemic treatment of melanoma brain metastases].
Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
11. Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administration-approved systemic therapies.
Walter JR; Xu S; Paller AS; Choi JN; Woodruff TK
J Am Acad Dermatol; 2016 Sep; 75(3):528-534. PubMed ID: 27543212
[TBL] [Abstract][Full Text] [Related]
12. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
14. The role of systemic therapies in the management of melanoma brain metastases.
Lyle M; Long GV
Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
[TBL] [Abstract][Full Text] [Related]
15. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
16. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O; Hoeller C
Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
19. [Understanding current therapies in metastatic melanoma].
Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
[TBL] [Abstract][Full Text] [Related]
20. Fertility preservation for patients with melanoma.
Filippi F; Serra N; Vigano P; Boeri L; Cimminiello C; Di Guardo L; Somigliana E; Del Vecchio M
Melanoma Res; 2022 Oct; 32(5):303-308. PubMed ID: 35855660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
